Regulatory press release

Nanexa AB changes Certified Adviser to Tapper Partners AB

Nanexa AB announces today that the company is changing its Certified Adviser to Tapper Partners AB.

Nanexa AB has entered into an agreement with Tapper Partners AB regarding the role as Certified Adviser. Tapper Partners AB will assume the role of Certified Adviser on October 1, 2025. Until then, DNB Carnegie Investment Bank AB will continue to act as the company's Certified Adviser.

About Nanexa AB (publ)

Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company’s proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of ‘super generic’ formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others.
Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).